PAVmed Inc ((PAVMU)), Pavmed ((PAVM)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The recent clinical study update from PAVmed Inc. focuses on the ‘First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System.’ The study aims to evaluate the safety and performance of the PortIO device, designed to provide non-emergent vascular access for chronic kidney disease patients, preserving venous anatomy and avoiding vein damage. This study is significant as it addresses the needs of patients with difficult vascular access.
The intervention being tested is the PAVmed PortIO™ Intraosseous Infusion System, a device intended to offer up to 60 days of intraosseous vascular access for fluid and medication delivery, inserted into specific bones in adults.
The study is interventional, with a single-group model and no masking, primarily focused on treatment. It is a prospective, open-label, single-arm, non-randomized, multicentric trial involving up to 40 subjects completing either a 7-day or 60-day implant duration.
The study began on January 20, 2022, and was completed with the last update submitted on June 24, 2025. These dates are crucial as they mark the progression and finalization of the study, providing a timeline for data analysis and potential market impact.
The completion of this study could positively influence PAVmed Inc.’s stock performance by demonstrating innovation in medical devices, potentially increasing investor confidence. In the competitive landscape of medical device companies, successful trial results could position PAVmed favorably against competitors.
The study has been completed, and further details are available on the ClinicalTrials portal.